Metformin does not improve the reproductive or metabolic profile in women with polycystic ovary syndrome (PCOS)

Mira Aubuchon, Harry J. Lieman, Daniel T. Stein, Hillel W. Cohen, Barbara Isaac, Goli Adel, Vanessa Weitzman, Maggie Tetrokalashvili, Alex J. Polotsky, Nanette Santoro

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

To determine whether metformin, when given to women with polycystic ovary syndrome (PCOS), promotes folliculogenesis by prompting a drop in free sex steroids resulting in a compensatory follicle stimulating hormone (FSH) rise, we conducted a randomized, double-blind, placebo-controlled crossover clinical trial. Eight mid-reproductive age PCOS participants with mean obese body mass index (BMI) and normal glucose tolerance received 8 weeks of metformin, given in a step-up fashion to a maximum dose of 2000 mg daily or placebo with daily urine sampling, 4-6 weeks washout, and crossover to the remaining arm for 8 weeks. To confirm the effects of metformin on glucose and other metabolic markers, a hyperinsulinemic, euglycemic 3-dose clamp (physiologic: 30 mU/m 2 per minute, high: 400 mU/m2 per minute) followed each treatment. Urinary FSH, luteinizing hormone (LH), or pregnanediol glucuronide (Pdg) did not differ by treatment. Glucose disposal, endogenous glucose production, BMI, ovulation rates, serum sex steroids, free fatty acids, and lipids did not significantly differ by treatment, despite good evidence for compliance with the protocol. During the clamp, high-dose insulin administration was associated with an acute drop in serum LH. We conclude that short-term, high-dose metformin exerts minimal effects on both metabolic markers and reproductive hormones in a small sample of overall morbidly obese women.

Original languageEnglish (US)
Pages (from-to)938-946
Number of pages9
JournalReproductive Sciences
Volume16
Issue number10
DOIs
StatePublished - Oct 2009

Fingerprint

Metabolome
Polycystic Ovary Syndrome
Metformin
Glucose
Follicle Stimulating Hormone
Luteinizing Hormone
Body Mass Index
Steroids
Placebos
Pregnanediol
Guideline Adherence
Glucuronides
Controlled Clinical Trials
Ovulation
Serum
Nonesterified Fatty Acids
Cross-Over Studies
Therapeutics
Urine
Hormones

Keywords

  • FSH
  • Insulin resistance
  • Metformin
  • Ovulation.
  • PCOS

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Metformin does not improve the reproductive or metabolic profile in women with polycystic ovary syndrome (PCOS). / Aubuchon, Mira; Lieman, Harry J.; Stein, Daniel T.; Cohen, Hillel W.; Isaac, Barbara; Adel, Goli; Weitzman, Vanessa; Tetrokalashvili, Maggie; Polotsky, Alex J.; Santoro, Nanette.

In: Reproductive Sciences, Vol. 16, No. 10, 10.2009, p. 938-946.

Research output: Contribution to journalArticle

Aubuchon, M, Lieman, HJ, Stein, DT, Cohen, HW, Isaac, B, Adel, G, Weitzman, V, Tetrokalashvili, M, Polotsky, AJ & Santoro, N 2009, 'Metformin does not improve the reproductive or metabolic profile in women with polycystic ovary syndrome (PCOS)', Reproductive Sciences, vol. 16, no. 10, pp. 938-946. https://doi.org/10.1177/1933719109340925
Aubuchon, Mira ; Lieman, Harry J. ; Stein, Daniel T. ; Cohen, Hillel W. ; Isaac, Barbara ; Adel, Goli ; Weitzman, Vanessa ; Tetrokalashvili, Maggie ; Polotsky, Alex J. ; Santoro, Nanette. / Metformin does not improve the reproductive or metabolic profile in women with polycystic ovary syndrome (PCOS). In: Reproductive Sciences. 2009 ; Vol. 16, No. 10. pp. 938-946.
@article{8f3785256e0d478f9c8faa94dd9047c7,
title = "Metformin does not improve the reproductive or metabolic profile in women with polycystic ovary syndrome (PCOS)",
abstract = "To determine whether metformin, when given to women with polycystic ovary syndrome (PCOS), promotes folliculogenesis by prompting a drop in free sex steroids resulting in a compensatory follicle stimulating hormone (FSH) rise, we conducted a randomized, double-blind, placebo-controlled crossover clinical trial. Eight mid-reproductive age PCOS participants with mean obese body mass index (BMI) and normal glucose tolerance received 8 weeks of metformin, given in a step-up fashion to a maximum dose of 2000 mg daily or placebo with daily urine sampling, 4-6 weeks washout, and crossover to the remaining arm for 8 weeks. To confirm the effects of metformin on glucose and other metabolic markers, a hyperinsulinemic, euglycemic 3-dose clamp (physiologic: 30 mU/m 2 per minute, high: 400 mU/m2 per minute) followed each treatment. Urinary FSH, luteinizing hormone (LH), or pregnanediol glucuronide (Pdg) did not differ by treatment. Glucose disposal, endogenous glucose production, BMI, ovulation rates, serum sex steroids, free fatty acids, and lipids did not significantly differ by treatment, despite good evidence for compliance with the protocol. During the clamp, high-dose insulin administration was associated with an acute drop in serum LH. We conclude that short-term, high-dose metformin exerts minimal effects on both metabolic markers and reproductive hormones in a small sample of overall morbidly obese women.",
keywords = "FSH, Insulin resistance, Metformin, Ovulation., PCOS",
author = "Mira Aubuchon and Lieman, {Harry J.} and Stein, {Daniel T.} and Cohen, {Hillel W.} and Barbara Isaac and Goli Adel and Vanessa Weitzman and Maggie Tetrokalashvili and Polotsky, {Alex J.} and Nanette Santoro",
year = "2009",
month = "10",
doi = "10.1177/1933719109340925",
language = "English (US)",
volume = "16",
pages = "938--946",
journal = "Reproductive Sciences",
issn = "1933-7191",
publisher = "SAGE Publications Inc.",
number = "10",

}

TY - JOUR

T1 - Metformin does not improve the reproductive or metabolic profile in women with polycystic ovary syndrome (PCOS)

AU - Aubuchon, Mira

AU - Lieman, Harry J.

AU - Stein, Daniel T.

AU - Cohen, Hillel W.

AU - Isaac, Barbara

AU - Adel, Goli

AU - Weitzman, Vanessa

AU - Tetrokalashvili, Maggie

AU - Polotsky, Alex J.

AU - Santoro, Nanette

PY - 2009/10

Y1 - 2009/10

N2 - To determine whether metformin, when given to women with polycystic ovary syndrome (PCOS), promotes folliculogenesis by prompting a drop in free sex steroids resulting in a compensatory follicle stimulating hormone (FSH) rise, we conducted a randomized, double-blind, placebo-controlled crossover clinical trial. Eight mid-reproductive age PCOS participants with mean obese body mass index (BMI) and normal glucose tolerance received 8 weeks of metformin, given in a step-up fashion to a maximum dose of 2000 mg daily or placebo with daily urine sampling, 4-6 weeks washout, and crossover to the remaining arm for 8 weeks. To confirm the effects of metformin on glucose and other metabolic markers, a hyperinsulinemic, euglycemic 3-dose clamp (physiologic: 30 mU/m 2 per minute, high: 400 mU/m2 per minute) followed each treatment. Urinary FSH, luteinizing hormone (LH), or pregnanediol glucuronide (Pdg) did not differ by treatment. Glucose disposal, endogenous glucose production, BMI, ovulation rates, serum sex steroids, free fatty acids, and lipids did not significantly differ by treatment, despite good evidence for compliance with the protocol. During the clamp, high-dose insulin administration was associated with an acute drop in serum LH. We conclude that short-term, high-dose metformin exerts minimal effects on both metabolic markers and reproductive hormones in a small sample of overall morbidly obese women.

AB - To determine whether metformin, when given to women with polycystic ovary syndrome (PCOS), promotes folliculogenesis by prompting a drop in free sex steroids resulting in a compensatory follicle stimulating hormone (FSH) rise, we conducted a randomized, double-blind, placebo-controlled crossover clinical trial. Eight mid-reproductive age PCOS participants with mean obese body mass index (BMI) and normal glucose tolerance received 8 weeks of metformin, given in a step-up fashion to a maximum dose of 2000 mg daily or placebo with daily urine sampling, 4-6 weeks washout, and crossover to the remaining arm for 8 weeks. To confirm the effects of metformin on glucose and other metabolic markers, a hyperinsulinemic, euglycemic 3-dose clamp (physiologic: 30 mU/m 2 per minute, high: 400 mU/m2 per minute) followed each treatment. Urinary FSH, luteinizing hormone (LH), or pregnanediol glucuronide (Pdg) did not differ by treatment. Glucose disposal, endogenous glucose production, BMI, ovulation rates, serum sex steroids, free fatty acids, and lipids did not significantly differ by treatment, despite good evidence for compliance with the protocol. During the clamp, high-dose insulin administration was associated with an acute drop in serum LH. We conclude that short-term, high-dose metformin exerts minimal effects on both metabolic markers and reproductive hormones in a small sample of overall morbidly obese women.

KW - FSH

KW - Insulin resistance

KW - Metformin

KW - Ovulation.

KW - PCOS

UR - http://www.scopus.com/inward/record.url?scp=70349287732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349287732&partnerID=8YFLogxK

U2 - 10.1177/1933719109340925

DO - 10.1177/1933719109340925

M3 - Article

VL - 16

SP - 938

EP - 946

JO - Reproductive Sciences

JF - Reproductive Sciences

SN - 1933-7191

IS - 10

ER -